Skip to main content

Table 2 Univariate and multivariate analysis of prognostic factors for OS in patients with DLBCL

From: Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis

Parameters Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age (>60 vs ≤60) 1.567 (0.850–2.891) 0.150   
Sex (male vs female) 1.008 (0.550–1.848) 0.980   
B symptoms (present vs absent) 2.302 (1.255–4.221) 0.007   
LDH (>ULN vs normal) 4.022 (2.026–7.984) <0.001   
ECOG score (2-4 vs 0-1) 2.785 (1.518–5.108) 0.001   
Ann Arbor Stage (III-IV vs I-II) 1.919 (0.967–3.810) 0.062   
Extranodal disease (>1 vs ≤1) 2.089 (1.144–3.815) 0.017   
IPI   <0.001   <0.001
 Low risk (0-1) reference   reference  
 Low-intermediate risk (2) 1.146 (0.408–3.219) 0.797 1.144 (0.407–3.215) 0.798
 High-intermediate risk (3) 4.044 (1.763–9.276) 0.001 3.516 (1.519–8.139) 0.003
 High risk (4-5) 5.441 (2.324–12.739) <0.001 4.722 (1.999–11.154) <0.001
Subtype (GCB vs non-GCB) 1.254 (0.795–1.979) 0.331   
FFAs (high vs normal) 2.698 (1.385–5.258) 0.004 2.075 (1.051–4.096) 0.035